Format

Send to

Choose Destination
Clin Proteomics. 2018 Apr 9;15:15. doi: 10.1186/s12014-018-9191-3. eCollection 2018.

Activation peptide of the coagulation factor XIII (AP-F13A1) as a new biomarker for the screening of colorectal cancer.

Author information

1
1Aix Marseille Univ, CNRS, INSERM, Institut Paoli-Calmettes, CRCM, Marseille Protéomique, Marseille, France, Aix Marseille Univ, 27 Bd Leï Roure, BP30059, 13273 Marseille Cedex 9, France.
2
PROFILOME SAS, 24 Rue du Faubourg Saint-Jacques, 75014 Paris, France.
3
3Present Address: Institute for Cell and Molecular Biosciences, Faculty of Medical Sciences, Institute for Cell and Molecular Biosciences, Newcastle University, Newcastle Upon Tyne, NE2 4HH UK.
4
Present Address: OncoDiag, Pépinière scientifique, Rue de Pacy, Miserey, France.

Abstract

Background:

Colorectal cancer (CRC) remains a major cause of cancer fatalities in developed countries. The risk of death is correlated to the stage of CRC during the primary diagnosis. Early diagnosis is closely associated with enhanced survival rate. We therefore investigated the AP-F13A1 as a potential protein marker of CRC.

Methods:

The protein expression of FXIII in 40 serum samples was evaluated by enzyme-linked immunosorbent assays. Additionally, targeted proteomic assays (LC-PRM) were used to evaluate the expression of the activation peptide of F13A1 (AP-F13A1) in a further 113 serum samples. Results were analyzed by the Wilcoxon test and receiver operating characteristic curves generated to assess statistical differences and diagnostic factors between CRC patients and controls.

Results:

AP-F13A1 was quantified in human serum samples using calibration curves with excellent linearity. AP-F13A1 was reduced in CRC patients using PRM assays from two distinct biobanks. The AUC for AP-F13A1 were 0.95 and 0.93. Sensitivity/specificity values for the two sets of patients were 75%/95% and 71%/95% respectively.

Conclusion:

We have presented the proof of principle that in vivo release of AP-F13A1 can be measured by PRM-based strategies in CRC serum samples. AP-F13A1 may be an effective serological biomarker as part of a screening program of CRC detection.

KEYWORDS:

AP-F13A1; Biomarker; Colorectal cancer; ELISA; LC-PRM

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center